2 Stocks Down 23% and 26% to Buy Right Now
If investors can see past the downturn in energy prices, Chevron stock is a great opportunity.
Exponential AI demand growth is driving this company's end-market growth.
10 stocks we like better than Chevron ›
With the first half of 2025 nearly over, many investors are taking time to reevaluate their portfolios and take advantage of quality stocks that can be bought at a discount. It certainly requires some confidence to buy shares of a company when they're down, but it's opportunities like these that offer the potential for outsize returns.
Two Fool.com contributors, for example, recognize that oil supermajor Chevron (NYSE: CVX) and data center equipment provider Vertiv (NYSE: VRT) are two worthy considerations for investors to click the buy buttons on right now since they're stocks are trading down 23% and 26%, respectively, from recent all-time highs.
(Chevron): While the 23% decline in Chevron stock from its all-time high in January 2023 may be disconcerting, the truth is that the stock's fall isn't wholly unexpected. There's a strong correlation between the movements of energy prices and those of energy stocks, so when investors pair Chevron stock's plunge with the 22% dip in the price of oil benchmark West Texas Intermediate during the same time period, the performance in Chevron's stock becomes much more understandable.
Whether you're on the prowl for a reliable dividend stock or a steady energy stock or something in between, Chevron fits the bill. For 38 consecutive years, the company has hiked its dividend -- a notable achievement for any company but especially one whose business revolves around commodities along with their cyclical prices. Lest investors fear that the company is sacrificing its financial health to placate shareholders, a peek at Chevron's average payout ratio over the past five years should allay their concerns: It's a conservative 68.4%.
Unlike some companies that solely focus on exploration and production, or those with midstream businesses, or downstream operations, Chevron operates throughout the energy value chain. This provides it with the ability to benefit from greater efficiencies than companies with more concentrated operations, as well as mitigating the risks associated with a slowing in the business of any one link in the energy value chain.
For those looking to put some pep in their passive income streams, now seems like a great time to gas up on Chevron stock.
Lee Samaha (Vertiv): Data center equipment provider and Nvidia partner Vertiv's stock trades down about 26% from its all-time high. It has recovered significantly recently, but despite a strong run, it's still an overall dip worth buying into.
That reasoning relies on assuming that we are in the early innings of investment in artificial intelligence (AI) applications and the data centers necessary to support AI growth. As recently discussed, there are no signs of a slowdown in data center spending, and that bodes well for the near-term outlook.
Thinking more medium-term, Vertiv's data center power systems are set to play a key role in the new generation of data centers that Nvidia is building toward. Nvidia believes the new 800-volt (V) high voltage direct current (HVDC) data centers (set to be launched in 2027) can improve efficiency by 5%, reduce copper usage, and lower maintenance costs by 70%, and also lower cooling costs.
The good news is that Vertiv plans to have its 800-V HVDC power systems ready by the second half of 2026, in time for deployment with Nvidia's key platform rollouts in 2027. That should drive the next cycle of orders at Vertiv, and as long as AI demand continues to explode, it's likely that Vertiv's total addressable market for its power systems, thermal management, and data center infrastructure will also grow strongly.
While semiconductor stocks often get the lion's share of attention regarding AI, Vertiv is a great consideration for investors looking to gain AI exposure -- especially with 2026 shaping up to an auspicious year of developments for the company. On the other hand, income investors who have the patience to wait out a downturn in energy prices have a great opportunity to power up their passive income streams right now with Chevron stock.
Before you buy stock in Chevron, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Chevron wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!*
Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Lee Samaha has no position in any of the stocks mentioned. Scott Levine has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chevron and Nvidia. The Motley Fool has a disclosure policy.
2 Stocks Down 23% and 26% to Buy Right Now was originally published by The Motley Fool
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine
Yahoo
2 hours ago
- Yahoo
What To Expect From Lennar's (LEN) Q2 Earnings
Homebuilder Lennar (NYSE:LEN) will be announcing earnings results tomorrow after market close. Here's what investors should know. Lennar beat analysts' revenue expectations by 2% last quarter, reporting revenues of $7.63 billion, up 4.4% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' EPS estimates but a miss of analysts' backlog estimates. Is Lennar a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Lennar's revenue to decline 5.5% year on year to $8.29 billion, a reversal from the 9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.94 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lennar has missed Wall Street's revenue estimates twice over the last two years. With Lennar being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for industrials stocks. However, investors in the segment have had steady hands going into earnings, with share prices flat over the last month. Lennar is down 2.3% during the same time and is heading into earnings with an average analyst price target of $132.69 (compared to the current share price of $108.64). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
9 hours ago
- Yahoo
How the U.S. is Handing Over Venezuela's Oil Sector to China
After coming into office, the administration of President Donald Trump has eliminated licenses for oil companies to operate in Venezuela, despite initial hints that it would continue them, with presidential envoy Richard Grenell's visits to Caracas. This means that sanctions on state-owned PDVSA are fully back on. Chevron, the main U.S. corporation on the ground, is back to having only a secret license for minimum maintenance and security, as it still a shareholder in four joint ventures. In the last few months, this has sparked a question. Is the U.S. government leaving the South American country at the mercy of Beijing? Could Chinese companies replace Chevron in Venezuela? There are two short answers. In terms of oil exports, yes. And this has already happened. Before the first round of economic and financial sanctions hit in 2017, the U.S. took almost 800,000 barrels per day from Venezuela. This figure went all the way down to zero in 2019, with the highest level of restrictions known as 'maximum pressure.' This happened again in May of this year, as Chevron, Repsol and others were blocked by the Treasury Department's Office of Foreign Assets Control (OFAC). So, where does all the oil go? In past years, Caracas was able to strike agreements with Rosneft or with Indian buyers. But as the U.S. introduced secondary sanctions, and now secondary tariffs, there was only one buyer left, the only one that does not fear Washington's threats: China. Reuters has already reported that crude that was produced in joint ventures with Chevron has been on its way to East Asia. And the Chinese market does have the capacity to absorb Venezuelan oil. The only problem is how much PDVSA gets paid, when there is only one buyer on the block—a monopsony. When it comes down to Chinese companies taking over Chevron's operations, this is unlikely to happen in the near to medium term. More than anything else, because it does not need to happen for Beijing to expand its influence and control. The same goes for Moscow or Iran. First, investors have plenty of options before them, from greenfield opportunities to mature fields that only need repairs. Venezuela has thousands of square kilometres with billions of barrels of oil underneath. And most joint ventures are effectively dormant: just 20 out of 64 areas of operation are producing more than 10,000 barrels per day of crude, while most are stuck at 0 or below the 1,000 mark. Second, regime officials will prefer to keep the fields where Chevron invested for themselves. 240,000 barrels per day is a great business opportunity. This means millions of dollars in contracts for goods and services, that used to be managed by a foreign corporation—not anymore, courtesy of President Trump. Can Chinese companies take over Chevron's oil fields? Now, Chinese companies entering Chevron's former operations can definitely happen. Let us start with Productive Participation Contracts (known as CPP for their initials in Spanish), which are a form of production-sharing agreement coupled with exclusive rights to contract goods and services. Hong Kong-based China Concord Petroleum (CCP) has started working in oil fields which are part of a joint venture with Belorusneft, using a CPP. Given that 'Petrolera Bielovenezolana' was not productive—with an average output of just 200 barrels per day—the Venezuelan government effectively put it up for rent. The Venezuelan government is not just signing production sharing agreements in areas where there are joint ventures; it is even figuring a way to normalise this framework. This could include that not just PDVSA, but the other shareholders in the joint venture get paid dividends as well by the CPP company. Thanks to the minimum maintenance license, Chevron is still a partner to PDVSA. But with no way to pay, the Venezuelan government feels entitled to remove it from operational control. In the coming years, it should be no surprise if a new company—Chinese or from any other country—effectively takes over. Here is another point that cannot be overlooked: CPPs are negotiated and signed in secret, since they were created under a special law to bypass sanctions. So far, we only know that CCP, Anhui Guangda Mining Investment and Kerui Petroleum Group have been eyeing up opportunities in Venezuela, but there could be more companies out there that we just do not know of yet. While Anhui Guangda has signed a deal for a greenfield project in the Orinoco Oil Belt—the Ayacucho 2 block—there are reports that these firms have also shown interest in the joint ventures where Petrobras was involved. China's mineral monopsony Oil is only one part of the story. In the mining sector, China and Iran are the only major foreign states. Initially, many U.S. and other Western companies left due to expropriations, especially during Hugo Chávez's expropriation spree between 2007 and 2012. But now, while there is more openness to foreign capital, the OFAC is sanctioning the gold sector, which makes the entire mining industry riskier. India's Jindal Steel & Power was nonetheless able to start up at the Cerro Bolívar iron mines last year. For some minerals, China is the only game in town. An example is cassiterite, a type of rock which contains tin (about 65%) and smaller quantities of tantalum, platinum and other rare minerals. Buyers are keeping production at arm's length, which is mostly done by artisanal mining. But they nonetheless have an outsized influence on the sector—this is a monopsony—and the same is happening with oil. By Elias Ferrer for More Top Reads From t Read this article on
